SlideShare a Scribd company logo
1 of 26
Download to read offline
D-Stereoisomers of Apo A-I Mimetic Peptides
Given Orally
Reduce Atherosclerosis in Mice
Mohamad Navab
UCLA Cardiology
Objective:
Identification of a class of peptides that are
orally administrable and that ameliorate one
or more symptoms of atherosclerosis.
Introduction:
We have reported that when LDL was incubated with
apoA-I or apo A-I peptide mimetics, LDL became
resistant to oxidation by artery wall cells in coculture.
Similarly, when the artery wall cells in culture were
pretreated with apoA-I, or the peptide mimetics, the
cells were no longer capable of oxidizing LDL.
Peripheral human monocytes pre-incubated with
apoA-I became similarly incapable of oxidizing LDL.
We showed that apoA-I removed, from LDL, the
“seeding molecules” HPETEs and HPODEs that are
required for LDL lipid oxidation.
ApoA-I and other exchangeable apolipoproteins,
possess lipid-associating domains.
Brouillette & Anantharamaiah (1995), Segrest et al. (1974)
Apo A-I has been postulated to possess eight tandem
repeating 22mer sequences, most of which have the
potential to form class A amphipathic helical structures.
(Segrest et al. 1974)
Apo A-I strongly associates with phospholipids to form
complexes and to promote cholesterol efflux from
cholesterol-enriched cells.
The delivery and maintenance of serum levels of apo A-I
to effectively mitigate one or more symptoms of
atherosclerosis has heretofore proven elusive.
Peptides comprising a class A amphipathic helix when
formulated with "D" amino acid residue(s) and/or having
protected amino and carboxyl termini can be:
- orally administered to an organism,
- are taken up and delivered to serum
- are effective to mitigate symptoms of
atherosclerosis.
Novel peptide administration of which mitigate one or
more symptoms of atherosclerosis.
The peptide ranges in length from about 10 to about 30
amino acids, at least one class A amphipathic helix,
at least one "D" amino acid residue, protects a
phospholipid against oxidation by an oxidizing agent,
Protecting groups include, acetyl, and amide groups
coupled to the amino terminus and the carboxyl
terminus.
Particularly preferred peptides comprise greater than
about 50% amino acid sequence identity with human or
mouse apo A-1 or with the polypeptide encoded by the
exon encoding a class A amphipathic helix of human or
mouse apo A-1.
Peptides formulated using D amino acids, the peptides
show dramatically elevated serum half-lives and,
particularly when the amino and/or carboxy termini are
blocked, can be orally administered.
Such D-form peptides retain the biological activity of
the corresponding L-form peptide. In vivo animal
studies using such D-form peptides showed effective
oral delivery, elevated serum half-life, and the ability to
mitigate or prevent/inhibit symptoms of
atherosclerosis.
Normal HDL inhibits three steps in the formation of
mildly oxidized LDL.
In those studies treating human LDL in vitro with apo A-
I or an apo A-I mimetic peptide removed seeding
molecules from the LDL that included HPODE and
HPETE.
These “seeding” molecules were required for cocultures
of human artery wall cells to be able to oxidize LDL and
for the LDL to induce the artery wall cells to produce
monocyte chemotactic activity.
We also demonstrated that after injection of apo A-I into
mice or infusion into humans, the LDL isolated from the
mice or human volunteers after injection/infusion of apo
A-I was resistant to oxidation by human artery wall cells
and did not induce monocyte chemotactic activity in the
artery wall cell cocultures.
It is noted that the fourth exon of apo A-I, when folded
into 3.667 residues/turn produces a class A amphipathic
helical structure.
One particularly preferred class A peptide, designated
18A (Anantharamaiah, 1986) was modified to produce
peptides orally administrable and highly effective at
inhibiting or preventing one or more symptoms of
atherosclerosis.
The peptides may act in vivo by picking up
“seeding molecule(s)” that mitigate oxidation of
LDL.
Anantharamaiah’s group determined that increasing
the number of Phe residues on the hydrophobic face
of the 18A would theoretically increase lipid affinity
as determined by computation. Palgunachari et al. (1996)
Apo A-I Peptide
Mimetic 2F
Hydrophobic face
Hydrophilic face
Amino group
Therefore, initially 5 additional Phe was chosen and
hence the peptides designation as 5F.
The 5F peptide was blocked in that the amino terminal
residue was acetylated and the carboxyl terminal residue
was amidated.
The new class A peptide analog, 5F inhibited , lesion
development in atherosclerosis-susceptible mice.
Garber et al. 2000
The peptides used are chemically synthesized using
standard chemical peptide synthesis techniques.
Peptides with an additional 2, 3 and 4 Phe would have
higher theoretical lipid affinity.
Theoretically, a systematic substitution of residues in the
nonpolar face of 18A with Phe could yield six peptides.
ApoA-1 mimetic peptides.
18A D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F
2F Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2
3F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2
3F14 Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2
4F Ac-D-W-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-NH2
5F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2
6F Ac-D-W-L-K-A-F-Y-D-K-F- F-E-K-F-K-E-F-F-NH2
7F Ac-D-W-F-K-A-F-Y-D-K-F-F- E-K-F-K-E-F-F-NH2
ApoA-I mimetic D-peptides prevent
LDL induced monocyte chemotactic activityMigratedmonocytesperHPF
D-2F L-2F D-37pA L-37pA
Assay controls
h
HDL
+
h
LDL
h
LDL
LDL, NO CELLS
CELLS, N0 LDL
µg
250
125
62
31
+ h LDL
250
125
62
31
0
1
2
3
4
5
6
7
8
9
10
250
125
62
31
250
125
62
31
Increased HDL protective capacity after oral peptide, D-4F in LDL R-/- mice
0
1
2
3
4
5
6
7
8
9
m HDL + LDL
Saline D - 4 FL- 4 F
MigratedmonocytesperHPF
100 µg50
P<.01
100 µg50 100 µg50
N
o
Addition
h
LD
L
h
LD
L
+h
H
D
L
H
D
L
Assay Controls
0
1
2
3
4
5
6
7
8
9
Saline L- 4F D - 4F
m VLDL+ m LDL
MigratedmonocytesperHPF
N
o
Addition
h
LD
L
h
LD
L
+
h
H
D
L
Assay Controls
m LDL
Saline L- 4F D-4F
P<.001
P<.001
Increased resistance to oxidation for LDL after oral peptide, D - 4F in LDL R-/- mice
FPLC Fraction Number
0
2
4
6
8
6050403020100
60504030201000
2
4
6
8
L-4F
D-4F
24 hr .
5 min. 45 min.
60504030201000
2
4
6
8
6050403020100
0
2
4
6
8
L-4F
D-4F
6050403020100
D-4F
6050403020100
0
2
4
6
8
0
2
4
6
8
L-4F
3 hr.
FPLC Fraction Number
6050403020100
0
2
4
6
8
6050403020100
0
2
4
6
8
D-4F
L-4F
Cholesterol,
mg/dl
0
10
20 LDL HDL
125
I,CPMx10-3
5040302010
125
I,CPMx10-3
Plasma radioactivity following oral administration of 125
I- 4F peptide
cpm/mlplasma
0
2,000
4,000
6,000
8,000
10,000
12,000
Intact
18 mer
Free
counts
L - 4F
6040200 10 30 50
D - 4F
0
cpm/mlplasma
2,000
4,000
6,000
8,000
10,000
12,000
6040200 10 30 50
Intact D-4F in plasma at 4 hrs
HPLC Fractions
High levels of radioactivity in mouse urine
following oral administration of 125
I - L- 4F
cpm/50µlurine
30 60 120 240 min
0
2 000 000
4 000 000
6 000 000
8 000 000
Time after gavage with 125
I-4F
L - 4F
D - 4F
20
30
40
50
60
70
80
90
100
110
120
130
Aorticrootlesionarea
µm2
x10-3
persection
D - 5 FSaline
84,495
50,100
41%
Reduction by D-5F of lesion scores in LDL receptor deficient mice on a Western type diet.
P<0.026
0
10
20
30
40
50
Saline D-5F
AorticsurfaceOROstain,µm2
8,800
21,500
59.06%
P<0.01
0
10
20
30
40
50
60
P< .01
81 %
Saline D- 4F
Aorticrootlesionarea
µm2
x10-3
persection
-
0
5
5
0
0
5
1
1
20
2
3
3 5
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Cholesterol(mg/dl)
FPLC Fractions
Control
D-4F
Plasma cholesterol in LDL R-/- mice gavaged with D-4F for 6 weeks
In Progress
0
5
10
15
20
25
30
35
40
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Cholesterol(mg/dl)
Control
D-4F
Plasma cholesterol in apoE null mice on D-4F in drinking water for 5 weeks
FPLC Fractions
PON activity in apoE null mice on D-4F in drinking water for 5 weeks
ParaoxonaseActivity,units/mlplasma
0
10
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Control
+ D-4F
2
4
6
8
FPLC Fractions
Peptides formulated using D amino acids show
dramatically elevated serum half-lives and, particularly
when the amino and/or carboxy termini are blocked, can
be orally administered.
Such D-form peptides retain the biological activity of the
corresponding L-form peptide. In vivo animal studies
using such D-form peptides showed effective oral
delivery, elevated serum half-life, and the ability to
markedly reduce atherosclerotic lesions.
Conclusion
Plans
- Determine tissue distribution
- Investigate potential cytotoxic effects
- preparation for studies in humans

More Related Content

What's hot

Biochemistry high yield points by GIMS
Biochemistry high yield points by GIMSBiochemistry high yield points by GIMS
Biochemistry high yield points by GIMS维卡普 Pardhu
 
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemia
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemiaFolic acid- Chemistry, One carbon metabolism and megaloblastic anemia
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemiaNamrata Chhabra
 
Inborn errors of purine and pyrimidine metabolism
Inborn errors of purine and pyrimidine metabolismInborn errors of purine and pyrimidine metabolism
Inborn errors of purine and pyrimidine metabolismRamesh Gupta
 
2 steroid metabolism
2   steroid metabolism2   steroid metabolism
2 steroid metabolismMUBOSScz
 
SOLID PHASE PEPTIDE SYNTHESIS
SOLID PHASE PEPTIDE SYNTHESISSOLID PHASE PEPTIDE SYNTHESIS
SOLID PHASE PEPTIDE SYNTHESISShikha Popali
 
3 steroid metabolism 2
3   steroid metabolism 23   steroid metabolism 2
3 steroid metabolism 2MUBOSScz
 
High yield enzymes for USMLE Step 1
High yield enzymes for USMLE Step 1High yield enzymes for USMLE Step 1
High yield enzymes for USMLE Step 1Osman Altohamy
 
Solid phase peptide synthesis
Solid phase peptide synthesisSolid phase peptide synthesis
Solid phase peptide synthesisABHISHEK SIRSIKAR
 
Amino acid analysis and peptide mapping Likhith K
Amino acid analysis  and peptide mapping Likhith KAmino acid analysis  and peptide mapping Likhith K
Amino acid analysis and peptide mapping Likhith KLIKHITHK1
 
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)Shikha Popali
 
Spps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesisSpps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesiskavyakaparthi1
 
12 lipids ii_-_eicosanoids__isoprenoids__steroids
12 lipids ii_-_eicosanoids__isoprenoids__steroids12 lipids ii_-_eicosanoids__isoprenoids__steroids
12 lipids ii_-_eicosanoids__isoprenoids__steroidsMUBOSScz
 
Plasma proteins by Dr Anurag Yadav
Plasma proteins by Dr Anurag YadavPlasma proteins by Dr Anurag Yadav
Plasma proteins by Dr Anurag YadavDr Anurag Yadav
 

What's hot (16)

BMCL Angibaud_ten Holte
BMCL Angibaud_ten HolteBMCL Angibaud_ten Holte
BMCL Angibaud_ten Holte
 
Biochemistry high yield points by GIMS
Biochemistry high yield points by GIMSBiochemistry high yield points by GIMS
Biochemistry high yield points by GIMS
 
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemia
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemiaFolic acid- Chemistry, One carbon metabolism and megaloblastic anemia
Folic acid- Chemistry, One carbon metabolism and megaloblastic anemia
 
Inborn errors of purine and pyrimidine metabolism
Inborn errors of purine and pyrimidine metabolismInborn errors of purine and pyrimidine metabolism
Inborn errors of purine and pyrimidine metabolism
 
2 steroid metabolism
2   steroid metabolism2   steroid metabolism
2 steroid metabolism
 
SOLID PHASE PEPTIDE SYNTHESIS
SOLID PHASE PEPTIDE SYNTHESISSOLID PHASE PEPTIDE SYNTHESIS
SOLID PHASE PEPTIDE SYNTHESIS
 
3 steroid metabolism 2
3   steroid metabolism 23   steroid metabolism 2
3 steroid metabolism 2
 
High yield enzymes for USMLE Step 1
High yield enzymes for USMLE Step 1High yield enzymes for USMLE Step 1
High yield enzymes for USMLE Step 1
 
Solid phase peptide synthesis
Solid phase peptide synthesisSolid phase peptide synthesis
Solid phase peptide synthesis
 
Overview of lipid metabolism
Overview of lipid metabolismOverview of lipid metabolism
Overview of lipid metabolism
 
Amino acid analysis and peptide mapping Likhith K
Amino acid analysis  and peptide mapping Likhith KAmino acid analysis  and peptide mapping Likhith K
Amino acid analysis and peptide mapping Likhith K
 
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)
Chemistry of peptide (BPHARM,MPHARM,MSC,BSC)
 
Spps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesisSpps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesis
 
12 lipids ii_-_eicosanoids__isoprenoids__steroids
12 lipids ii_-_eicosanoids__isoprenoids__steroids12 lipids ii_-_eicosanoids__isoprenoids__steroids
12 lipids ii_-_eicosanoids__isoprenoids__steroids
 
Plasma proteins by Dr Anurag Yadav
Plasma proteins by Dr Anurag YadavPlasma proteins by Dr Anurag Yadav
Plasma proteins by Dr Anurag Yadav
 
Plasma Proteins
Plasma ProteinsPlasma Proteins
Plasma Proteins
 

Viewers also liked

Viewers also liked (19)

Esv2n14
Esv2n14Esv2n14
Esv2n14
 
Detection of vp with spectroscopy
Detection of vp with spectroscopyDetection of vp with spectroscopy
Detection of vp with spectroscopy
 
Esv2n28
Esv2n28Esv2n28
Esv2n28
 
Harvey hecht md aeha sat
Harvey hecht md aeha satHarvey hecht md aeha sat
Harvey hecht md aeha sat
 
Elastography
ElastographyElastography
Elastography
 
Editorialslides v2n9
Editorialslides v2n9Editorialslides v2n9
Editorialslides v2n9
 
Dropped ismrm2001-mri spio
Dropped ismrm2001-mri spioDropped ismrm2001-mri spio
Dropped ismrm2001-mri spio
 
Final clickable pps for vp s ymposium @aha 2001
Final clickable pps for vp s ymposium @aha 2001Final clickable pps for vp s ymposium @aha 2001
Final clickable pps for vp s ymposium @aha 2001
 
Drleakeresearch
DrleakeresearchDrleakeresearch
Drleakeresearch
 
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
 
504 percutaneouse coronary intervention
504 percutaneouse coronary intervention504 percutaneouse coronary intervention
504 percutaneouse coronary intervention
 
Esv2n30
Esv2n30Esv2n30
Esv2n30
 
Detection of production preliminary
Detection of production preliminaryDetection of production preliminary
Detection of production preliminary
 
167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media167 plaque p h heterogeneity in physiological media
167 plaque p h heterogeneity in physiological media
 
247 ebct vs conventional risk factors
247 ebct vs conventional risk factors247 ebct vs conventional risk factors
247 ebct vs conventional risk factors
 
Embolic protection devices yadav- cleveland clinic
Embolic protection devices  yadav- cleveland clinicEmbolic protection devices  yadav- cleveland clinic
Embolic protection devices yadav- cleveland clinic
 
252 statin therapy influence on coronary calcification
252 statin therapy influence on coronary calcification252 statin therapy influence on coronary calcification
252 statin therapy influence on coronary calcification
 
Genetic influence ppt11
Genetic influence ppt11Genetic influence ppt11
Genetic influence ppt11
 
Dna microarray application in vp research mehran
Dna microarray application in vp research  mehranDna microarray application in vp research  mehran
Dna microarray application in vp research mehran
 

Similar to From pneumonia to influenza

213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosisSHAPE Society
 
Structure lipoproteins
Structure lipoproteinsStructure lipoproteins
Structure lipoproteinseman youssif
 
Structure lipoproteins
Structure lipoproteinsStructure lipoproteins
Structure lipoproteinseman youssif
 
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...Apollo Hospitals
 
Strategie nutraceutiche per ridurre l'infiammazione.
Strategie nutraceutiche per ridurre l'infiammazione.Strategie nutraceutiche per ridurre l'infiammazione.
Strategie nutraceutiche per ridurre l'infiammazione.CreAgri Europe
 
PhD thesis 2004
PhD thesis 2004PhD thesis 2004
PhD thesis 2004michielvds
 
Hugh Thompson P3 Summer Placement report 2014 (1)
Hugh Thompson P3 Summer Placement report 2014 (1)Hugh Thompson P3 Summer Placement report 2014 (1)
Hugh Thompson P3 Summer Placement report 2014 (1)Hugh E G Thompson
 
Lecture 1 part.1 Structure and Function of Nucleic Acid
Lecture 1 part.1 Structure and Function of Nucleic AcidLecture 1 part.1 Structure and Function of Nucleic Acid
Lecture 1 part.1 Structure and Function of Nucleic AcidDrQuratulAin5
 
Amino acid biosynthesis grp assignment ppt
Amino acid biosynthesis grp assignment pptAmino acid biosynthesis grp assignment ppt
Amino acid biosynthesis grp assignment pptGloria Okenze
 
Pharmaceutical Chemistry - Last part.pptx
Pharmaceutical Chemistry - Last part.pptxPharmaceutical Chemistry - Last part.pptx
Pharmaceutical Chemistry - Last part.pptxMathabhanga College
 
Does allicin combined with vitamin B-complex have superior potentials than α-...
Does allicin combined with vitamin B-complex have superior potentials than α-...Does allicin combined with vitamin B-complex have superior potentials than α-...
Does allicin combined with vitamin B-complex have superior potentials than α-...Prof. Hesham N. Mustafa
 
Ch 9 Lipid2.ppt
Ch 9 Lipid2.pptCh 9 Lipid2.ppt
Ch 9 Lipid2.pptcarlmanaay
 
I paraguariensis as option for weight management presentation
I paraguariensis as option for weight management presentationI paraguariensis as option for weight management presentation
I paraguariensis as option for weight management presentationFabiana N. Fonseca, Ph.D.
 
Kristi Hemstreet Journal Club 110711
Kristi Hemstreet Journal Club 110711Kristi Hemstreet Journal Club 110711
Kristi Hemstreet Journal Club 110711Kristi Hemstreet
 

Similar to From pneumonia to influenza (20)

213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis
 
Structure lipoproteins
Structure lipoproteinsStructure lipoproteins
Structure lipoproteins
 
Structure lipoproteins
Structure lipoproteinsStructure lipoproteins
Structure lipoproteins
 
Apolipo proteins
Apolipo proteinsApolipo proteins
Apolipo proteins
 
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...
Protective Effect of Phyllanthus Amarus by Modulation of Endogenous Biomarker...
 
Strategie nutraceutiche per ridurre l'infiammazione.
Strategie nutraceutiche per ridurre l'infiammazione.Strategie nutraceutiche per ridurre l'infiammazione.
Strategie nutraceutiche per ridurre l'infiammazione.
 
PhD thesis 2004
PhD thesis 2004PhD thesis 2004
PhD thesis 2004
 
Hugh Thompson P3 Summer Placement report 2014 (1)
Hugh Thompson P3 Summer Placement report 2014 (1)Hugh Thompson P3 Summer Placement report 2014 (1)
Hugh Thompson P3 Summer Placement report 2014 (1)
 
Lecture 1 part.1 Structure and Function of Nucleic Acid
Lecture 1 part.1 Structure and Function of Nucleic AcidLecture 1 part.1 Structure and Function of Nucleic Acid
Lecture 1 part.1 Structure and Function of Nucleic Acid
 
Amino acid biosynthesis grp assignment ppt
Amino acid biosynthesis grp assignment pptAmino acid biosynthesis grp assignment ppt
Amino acid biosynthesis grp assignment ppt
 
Plin5
Plin5Plin5
Plin5
 
Febuxostat Case Study
Febuxostat Case StudyFebuxostat Case Study
Febuxostat Case Study
 
Pharmaceutical Chemistry - Last part.pptx
Pharmaceutical Chemistry - Last part.pptxPharmaceutical Chemistry - Last part.pptx
Pharmaceutical Chemistry - Last part.pptx
 
D043022027
D043022027D043022027
D043022027
 
D043022027
D043022027D043022027
D043022027
 
Does allicin combined with vitamin B-complex have superior potentials than α-...
Does allicin combined with vitamin B-complex have superior potentials than α-...Does allicin combined with vitamin B-complex have superior potentials than α-...
Does allicin combined with vitamin B-complex have superior potentials than α-...
 
Ch 9 Lipid2.ppt
Ch 9 Lipid2.pptCh 9 Lipid2.ppt
Ch 9 Lipid2.ppt
 
I paraguariensis as option for weight management presentation
I paraguariensis as option for weight management presentationI paraguariensis as option for weight management presentation
I paraguariensis as option for weight management presentation
 
Surfactant
SurfactantSurfactant
Surfactant
 
Kristi Hemstreet Journal Club 110711
Kristi Hemstreet Journal Club 110711Kristi Hemstreet Journal Club 110711
Kristi Hemstreet Journal Club 110711
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 

Recently uploaded (20)

Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 

From pneumonia to influenza

  • 1. D-Stereoisomers of Apo A-I Mimetic Peptides Given Orally Reduce Atherosclerosis in Mice Mohamad Navab UCLA Cardiology
  • 2. Objective: Identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
  • 3. Introduction: We have reported that when LDL was incubated with apoA-I or apo A-I peptide mimetics, LDL became resistant to oxidation by artery wall cells in coculture. Similarly, when the artery wall cells in culture were pretreated with apoA-I, or the peptide mimetics, the cells were no longer capable of oxidizing LDL. Peripheral human monocytes pre-incubated with apoA-I became similarly incapable of oxidizing LDL. We showed that apoA-I removed, from LDL, the “seeding molecules” HPETEs and HPODEs that are required for LDL lipid oxidation.
  • 4. ApoA-I and other exchangeable apolipoproteins, possess lipid-associating domains. Brouillette & Anantharamaiah (1995), Segrest et al. (1974) Apo A-I has been postulated to possess eight tandem repeating 22mer sequences, most of which have the potential to form class A amphipathic helical structures. (Segrest et al. 1974) Apo A-I strongly associates with phospholipids to form complexes and to promote cholesterol efflux from cholesterol-enriched cells. The delivery and maintenance of serum levels of apo A-I to effectively mitigate one or more symptoms of atherosclerosis has heretofore proven elusive.
  • 5. Peptides comprising a class A amphipathic helix when formulated with "D" amino acid residue(s) and/or having protected amino and carboxyl termini can be: - orally administered to an organism, - are taken up and delivered to serum - are effective to mitigate symptoms of atherosclerosis. Novel peptide administration of which mitigate one or more symptoms of atherosclerosis.
  • 6. The peptide ranges in length from about 10 to about 30 amino acids, at least one class A amphipathic helix, at least one "D" amino acid residue, protects a phospholipid against oxidation by an oxidizing agent, Protecting groups include, acetyl, and amide groups coupled to the amino terminus and the carboxyl terminus. Particularly preferred peptides comprise greater than about 50% amino acid sequence identity with human or mouse apo A-1 or with the polypeptide encoded by the exon encoding a class A amphipathic helix of human or mouse apo A-1.
  • 7. Peptides formulated using D amino acids, the peptides show dramatically elevated serum half-lives and, particularly when the amino and/or carboxy termini are blocked, can be orally administered. Such D-form peptides retain the biological activity of the corresponding L-form peptide. In vivo animal studies using such D-form peptides showed effective oral delivery, elevated serum half-life, and the ability to mitigate or prevent/inhibit symptoms of atherosclerosis.
  • 8. Normal HDL inhibits three steps in the formation of mildly oxidized LDL. In those studies treating human LDL in vitro with apo A- I or an apo A-I mimetic peptide removed seeding molecules from the LDL that included HPODE and HPETE. These “seeding” molecules were required for cocultures of human artery wall cells to be able to oxidize LDL and for the LDL to induce the artery wall cells to produce monocyte chemotactic activity. We also demonstrated that after injection of apo A-I into mice or infusion into humans, the LDL isolated from the mice or human volunteers after injection/infusion of apo A-I was resistant to oxidation by human artery wall cells and did not induce monocyte chemotactic activity in the artery wall cell cocultures.
  • 9. It is noted that the fourth exon of apo A-I, when folded into 3.667 residues/turn produces a class A amphipathic helical structure. One particularly preferred class A peptide, designated 18A (Anantharamaiah, 1986) was modified to produce peptides orally administrable and highly effective at inhibiting or preventing one or more symptoms of atherosclerosis. The peptides may act in vivo by picking up “seeding molecule(s)” that mitigate oxidation of LDL.
  • 10. Anantharamaiah’s group determined that increasing the number of Phe residues on the hydrophobic face of the 18A would theoretically increase lipid affinity as determined by computation. Palgunachari et al. (1996) Apo A-I Peptide Mimetic 2F Hydrophobic face Hydrophilic face Amino group
  • 11. Therefore, initially 5 additional Phe was chosen and hence the peptides designation as 5F. The 5F peptide was blocked in that the amino terminal residue was acetylated and the carboxyl terminal residue was amidated. The new class A peptide analog, 5F inhibited , lesion development in atherosclerosis-susceptible mice. Garber et al. 2000 The peptides used are chemically synthesized using standard chemical peptide synthesis techniques. Peptides with an additional 2, 3 and 4 Phe would have higher theoretical lipid affinity. Theoretically, a systematic substitution of residues in the nonpolar face of 18A with Phe could yield six peptides.
  • 12. ApoA-1 mimetic peptides. 18A D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F 2F Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2 3F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2 3F14 Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2 4F Ac-D-W-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-NH2 5F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2 6F Ac-D-W-L-K-A-F-Y-D-K-F- F-E-K-F-K-E-F-F-NH2 7F Ac-D-W-F-K-A-F-Y-D-K-F-F- E-K-F-K-E-F-F-NH2
  • 13. ApoA-I mimetic D-peptides prevent LDL induced monocyte chemotactic activityMigratedmonocytesperHPF D-2F L-2F D-37pA L-37pA Assay controls h HDL + h LDL h LDL LDL, NO CELLS CELLS, N0 LDL µg 250 125 62 31 + h LDL 250 125 62 31 0 1 2 3 4 5 6 7 8 9 10 250 125 62 31 250 125 62 31
  • 14. Increased HDL protective capacity after oral peptide, D-4F in LDL R-/- mice 0 1 2 3 4 5 6 7 8 9 m HDL + LDL Saline D - 4 FL- 4 F MigratedmonocytesperHPF 100 µg50 P<.01 100 µg50 100 µg50 N o Addition h LD L h LD L +h H D L H D L Assay Controls
  • 15. 0 1 2 3 4 5 6 7 8 9 Saline L- 4F D - 4F m VLDL+ m LDL MigratedmonocytesperHPF N o Addition h LD L h LD L + h H D L Assay Controls m LDL Saline L- 4F D-4F P<.001 P<.001 Increased resistance to oxidation for LDL after oral peptide, D - 4F in LDL R-/- mice
  • 16. FPLC Fraction Number 0 2 4 6 8 6050403020100 60504030201000 2 4 6 8 L-4F D-4F 24 hr . 5 min. 45 min. 60504030201000 2 4 6 8 6050403020100 0 2 4 6 8 L-4F D-4F 6050403020100 D-4F 6050403020100 0 2 4 6 8 0 2 4 6 8 L-4F 3 hr. FPLC Fraction Number 6050403020100 0 2 4 6 8 6050403020100 0 2 4 6 8 D-4F L-4F Cholesterol, mg/dl 0 10 20 LDL HDL 125 I,CPMx10-3 5040302010 125 I,CPMx10-3 Plasma radioactivity following oral administration of 125 I- 4F peptide
  • 17. cpm/mlplasma 0 2,000 4,000 6,000 8,000 10,000 12,000 Intact 18 mer Free counts L - 4F 6040200 10 30 50 D - 4F 0 cpm/mlplasma 2,000 4,000 6,000 8,000 10,000 12,000 6040200 10 30 50 Intact D-4F in plasma at 4 hrs HPLC Fractions
  • 18. High levels of radioactivity in mouse urine following oral administration of 125 I - L- 4F cpm/50µlurine 30 60 120 240 min 0 2 000 000 4 000 000 6 000 000 8 000 000 Time after gavage with 125 I-4F L - 4F D - 4F
  • 19. 20 30 40 50 60 70 80 90 100 110 120 130 Aorticrootlesionarea µm2 x10-3 persection D - 5 FSaline 84,495 50,100 41% Reduction by D-5F of lesion scores in LDL receptor deficient mice on a Western type diet. P<0.026
  • 21. 0 10 20 30 40 50 60 P< .01 81 % Saline D- 4F Aorticrootlesionarea µm2 x10-3 persection
  • 22. - 0 5 5 0 0 5 1 1 20 2 3 3 5 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Cholesterol(mg/dl) FPLC Fractions Control D-4F Plasma cholesterol in LDL R-/- mice gavaged with D-4F for 6 weeks
  • 23. In Progress 0 5 10 15 20 25 30 35 40 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Cholesterol(mg/dl) Control D-4F Plasma cholesterol in apoE null mice on D-4F in drinking water for 5 weeks FPLC Fractions
  • 24. PON activity in apoE null mice on D-4F in drinking water for 5 weeks ParaoxonaseActivity,units/mlplasma 0 10 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Control + D-4F 2 4 6 8 FPLC Fractions
  • 25. Peptides formulated using D amino acids show dramatically elevated serum half-lives and, particularly when the amino and/or carboxy termini are blocked, can be orally administered. Such D-form peptides retain the biological activity of the corresponding L-form peptide. In vivo animal studies using such D-form peptides showed effective oral delivery, elevated serum half-life, and the ability to markedly reduce atherosclerotic lesions. Conclusion
  • 26. Plans - Determine tissue distribution - Investigate potential cytotoxic effects - preparation for studies in humans